QALY league table of Iran: a practical method for better resource allocation.
Cost effectiveness analysis
Cost utility analysis
Economic evaluation
Iran
Journal
Cost effectiveness and resource allocation : C/E
ISSN: 1478-7547
Titre abrégé: Cost Eff Resour Alloc
Pays: England
ID NLM: 101170476
Informations de publication
Date de publication:
13 Jan 2021
13 Jan 2021
Historique:
received:
11
04
2020
accepted:
11
12
2020
revised:
24
11
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
15
1
2021
Statut:
epublish
Résumé
The limited health care resources cannot meet all the demands of the society. Thus, decision makers have to choose feasible interventions and reject the others. We aimed to collect and summarize the results of all cost utility analysis studies that were conducted in Iran and develop a Quality Adjusted Life Year (QALY) league table. A systematic mapping review was conducted to identify all cost utility analysis studies done in Iran and then map them in a table. PubMed, Embase, Cochrane library, Web of Science, as well as Iranian databases like Iran Medex, SID, Magiran, and Barakat Knowledge Network System were all searched for articles published from the inception of the databases to January 2020. Additionally, Cost per QALY or Incremental Cost Utility Ratio (ICUR) were collected from all studies. The Joanna Briggs checklist was used to assess quality appraisal. In total, 51 cost-utility studies were included in the final analysis, out of which 14 studies were on cancer, six studies on coronary heart diseases. Two studies, each on hemophilia, multiple sclerosis and rheumatoid arthritis. The rest were on various other diseases. Markov model was the commonest one which has been applied to in 45% of the reviewed studies. Discount rates ranged from zero to 7.2%. The cost per QALY ranged from $ 0.144 in radiography costs for patients with some orthopedic problems to $ 4,551,521 for immune tolerance induction (ITI) therapy in hemophilia patients. High heterogeneity was revealed; therefore, it would be biased to rank interventions based on reported cost per QALY or ICUR. However, it is instructive and informative to collect all economic evaluation studies and summarize them in a table. The information on the table would in turn be used to redirect resources for efficient allocation. in general, it was revealed that preventive programs are cost effective interventions from different perspectives in Iran.
Sections du résumé
BACKGROUND
BACKGROUND
The limited health care resources cannot meet all the demands of the society. Thus, decision makers have to choose feasible interventions and reject the others. We aimed to collect and summarize the results of all cost utility analysis studies that were conducted in Iran and develop a Quality Adjusted Life Year (QALY) league table.
METHODS
METHODS
A systematic mapping review was conducted to identify all cost utility analysis studies done in Iran and then map them in a table. PubMed, Embase, Cochrane library, Web of Science, as well as Iranian databases like Iran Medex, SID, Magiran, and Barakat Knowledge Network System were all searched for articles published from the inception of the databases to January 2020. Additionally, Cost per QALY or Incremental Cost Utility Ratio (ICUR) were collected from all studies. The Joanna Briggs checklist was used to assess quality appraisal.
RESULTS
RESULTS
In total, 51 cost-utility studies were included in the final analysis, out of which 14 studies were on cancer, six studies on coronary heart diseases. Two studies, each on hemophilia, multiple sclerosis and rheumatoid arthritis. The rest were on various other diseases. Markov model was the commonest one which has been applied to in 45% of the reviewed studies. Discount rates ranged from zero to 7.2%. The cost per QALY ranged from $ 0.144 in radiography costs for patients with some orthopedic problems to $ 4,551,521 for immune tolerance induction (ITI) therapy in hemophilia patients. High heterogeneity was revealed; therefore, it would be biased to rank interventions based on reported cost per QALY or ICUR.
CONCLUSIONS
CONCLUSIONS
However, it is instructive and informative to collect all economic evaluation studies and summarize them in a table. The information on the table would in turn be used to redirect resources for efficient allocation. in general, it was revealed that preventive programs are cost effective interventions from different perspectives in Iran.
Identifiants
pubmed: 33441153
doi: 10.1186/s12962-020-00256-2
pii: 10.1186/s12962-020-00256-2
pmc: PMC7807517
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3Références
Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M. Systematic overview of cost–effectiveness thresholds in ten countries across four continents. J Compar Effect Res. 2015;4:485–504.
Haghparast-Bidgoli H, Kiadaliri AA, Skordis-Worrall J. Do economic evaluation studies inform effective healthcare resource allocation in Iran? A critical review of the literature. Cost Effect Resour Alloc. 2014;12:15.
Ong KS, Carter R, Vos T, Kelaher M, Anderson I. Cost-effectiveness of interventions to prevent cardiovascular disease in Australia’s indigenous population. Heart Lung Circ. 2014;23:414–21.
pubmed: 24252448
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
Horton S, Gelband H, Jamison D, Levin C, Nugent R, Watkins D. Ranking 93 health interventions for low-and middle-income countries by cost-effectiveness. PLoS ONE. 2017;12:e0182951.
pubmed: 28797115
pmcid: 5552255
Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–24.
pubmed: 25883405
Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36:509–22.
pubmed: 29427072
Crown W, Buyukkaramikli N, Thokala P, Morton A, Sir MY, Marshall DA, Tosh J, Padula WV, Ijzerman MJ, Wong PK. Constrained optimization methods in health services research—an introduction: report 1 of the ISPOR optimization methods emerging good practices task force. Value Health. 2017;20:310–9.
pubmed: 28292475
Greenberg D, Earle C, Fang C-H, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost–utility analyses in oncology. J Natl Cancer Inst. 2010;102:82–8.
Horton S. Cost-effectiveness analysis in disease control priorities. 2017.
Tashobya CK, Dubourg D, Ssengooba F, Speybroeck N, Macq J, Criel B. A comparison of hierarchical cluster analysis and league table rankings as methods for analysis and presentation of district health system performance data in Uganda. Health Policy Plan. 2015;31:217–28.
pubmed: 26024882
pmcid: 4748130
Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014;32:525–31.
pubmed: 24791735
Patel HD, Roberts ET, Constenla DO. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Vaccine. 2013;31:6072–8.
pubmed: 24176497
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
pubmed: 25554246
pmcid: 4320440
Institute JB. JBI Critical Appraisal tools for use in JBI Systematic Reviews: Checklist for Economic Evaluations. Australia; 2016.
Haghighat S, Akbari ME, Yavari P, Javanbakht M, Ghaffari S. Cost-effectiveness of three rounds of mammography breast cancer screening in Iranian women. Iran J Cancer Prev. 2016;9:1.
Aboutorabi A, Hadian M, Ghaderi H, Salehi M, Ghiasipour M. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Global J Health Sci. 2015;7:98.
Hatam N, Ahmadloo N, Vazirzadeh M, Jafari A, Askarian M. Cost-effectiveness of intensive vs. standard follow-up models for patients with breast cancer in Shiraz, Iran. Asian Pac J Cancer Prev. 2016;17:5309.
pubmed: 28125878
pmcid: 5454675
Hatam N, Askarian M, Javan-Noghabi J, Ahmadloo N, Mohammadianpanah M. Costutility of “Doxorubicin and Cyclophosphamide” versus “Gemcitabine and Paclitaxel” for treatment of patients with breast cancer in Iran. Asian Pac J Cancer Prev. 2015;16:8265–70.
pubmed: 26745071
Bastani P, Kiadaliri AA. Cost-utility analysis of adjuvant therapies for breast cancer in Iran. Int J Technol Assess Health Care. 2012;28:110–4.
pubmed: 22559752
Khatibi M, Rasekh HR, Shahverdi Z. Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iran J Pharm Res. 2014;13:225.
pubmed: 24711850
pmcid: 3977074
Barouni M, Larizadeh MH, Sabermahani A, Ghaderi H. Markovs Modeling for Screening Strategies for Colorectal Cancer. Asian Pac J Cancer Prev. 2012;13:5125–9.
pubmed: 23244122
Sari AA, Ravaghi H, Mobinizadeh M, Sarvari S. The cost-utility analysis of PET-scan in diagnosis and treatment of non-small cell lung carcinoma in Iran. Iran J Radiol. 2013;10:61.
Hajiesmaeili M, Yousefi M, Mahboub-Ahari A, Seyyednejad F. Cost effectiveness of lung cancer screening. Tabriz University of Medical Science, 2017.
Khezeli MJ, Dehghani M, Keshavarz K, Kavosi Z. Cost-utility analysis of the EOX drug regimen versus the DCF drug regimen for patients with advanced gastric cancer. Middle East J Cancer. 2019;10:118–24.
Amirsadri M, Sedighi MJ. Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran. Res Pharm Sci. 2017;12:144.
pubmed: 28515767
pmcid: 5385729
Amirsadri M, Hassani A. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men. DARU Journal of Pharmaceutical Sciences. 2015;23:56.
pubmed: 26717884
pmcid: 4697320
Javanbakht M, Bakhsh RY, Mashayekhi A, Ghaderi H, Sadeghi M. Coronary bypass surgery versus percutaneous coronary intervention: Cost-effectiveness in Iran: A study in patients with multivessel coronary artery disease. Int J Technol Assess Health Care. 2014;30:366–73.
pubmed: 25401422
Amiri A, Goudarzi R, Amiresmaili M, Iranmanesh F. Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran. J Med Econ. 2018;21:282–7.
pubmed: 29105528
Yaghoubi M, Aghayan HR, Arjmand B, Emami-Razavi SH. Cost-effectiveness of homograft heart valve replacement surgery: an introductory study. Cell Tissue Bank. 2011;12:153–8.
pubmed: 19949875
Amirsadri M, Mousavi S, Karimipour A. The cost-effectiveness and cost-utility analysis of the use of enoxaparin compared with heparin for venous thromboembolism prophylaxis in medical inpatients in Iran. DARU J Pharm Sci. 2019;27:627–34.
Mahboub-Ahari A, Hajebrahimi S, Yusefi M, Velayati A. EOS imaging versus current radiography: A health technology assessment study. Med J Islamic Republic of Iran. 2016;30:331.
Toroski M, Nikfar S, Mojahedian MM, Ayati MH. Comparison of the cost-utility Analysis of Electroacupuncture and Nonsteroidal Antiinflammatory Drugs in the Treatment of Chronic Low Back Pain. J Acupunct Meridian Stud. 2018;11:62–6.
pubmed: 29436371
Azar AAEF, Rezapour A, Alipour V, Sarabi-Asiabar A, Gray S, Mobinizadeh M, Yousefvand M, Arabloo J. Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran. Med J Islamic Republic of Iran. 2017;31:39.
Ahmadiani S, Nikfar S, Karimi S, Jamshidi AR, Akbari-Sari A, Kebriaeezadeh A. Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis. Rheumatol Int. 2016;36:1291–300.
pubmed: 27136919
Taheri S, Fashami FM, Peiravian F, Yousefi P. Teriparatide in the treatment of severe postmenopausal osteoporosis: a cost-utility analysis. Iran J Pharm Res. 2019;18:1073.
pubmed: 31531089
pmcid: 6706718
Hashemi-Meshkini A, Nikfar S, Glaser E, Jamshidi A, Hosseini SA. Cost-effectiveness analysis of tocilizumab in comparison with infliximab in iranian rheumatoid arthritis patients with inadequate response to tDMARDs: a multistage Markov model. Value Health Regional Issues. 2016;9:42–8.
Derakhshan F, Afsharzadeh N, Barouni M, Jafari M. Cost effectiveness of Osteoporosis Screening in Kerman. School of Health Information and Management, Kerman University of Medical.
Hatam N, Askarian M, Shirvani S, Purmohamadi K. Cost Utility of Neonatal Screening Program for Phenylketonuria in Shiraz University of Medical Sciences. 2014.
Hatam N, Askarian M, Bastani P, Pourmohammadi K, Shirvani S. Cost-Utility of Screening Program for Neonatal Hypothyroidism in Iran. Shiraz E-Medical Journal 2016, 17.
Hatam N, Askarian M, Shirvani S, Siavashi E. Neonatal screening: cost-utility analysis for Galactosemia. Iran J Public Health. 2017;46:112.
pubmed: 28451536
pmcid: 5401919
Hatam N, Shirvani S, Javanbakht M, Askarian M, Rastegar M. Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010. Iran J Pediatrics. 2013;23:493.
Keshavarz K, Kebriaeezadeh A, Alavian SM, Sari AA, Hemami MR, Lotfi F, Meshkini AH, Javanbakht M, Keshvari M, Nikfar S. A cost-utility and cost-effectiveness analysis of different oral antiviral medications in patients with HBeAg-negative chronic hepatitis B in Iran: an economic microsimulation decision model. Hepatitis Monthly. 2016;16:1.
Alavian SM, Nikfar S, Kebriaeezadeh A, Lotfi F, Sanati E, Hemami MR, Keshavarz K. A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iran Red Cresc Med J. 2016;18:1.
Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian M-A, Henry D, Sari AA. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. DARU J Pharm Sci. 2013;21:50.
Imani A, Golestani M. Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran. Iran J Neurol. 2012;11:87.
pubmed: 24250871
pmcid: 3829258
Taheri S, Sahraian MA, Yousefi N. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. J Med Econ. 2019;22:71–84.
pubmed: 30380350
Rezaee M, Izadi S, Keshavarz K, Borhanihaghighi A, Ravangard R. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. Journal of medical economics. 2019;22:297–305.
pubmed: 30561242
Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B. Cost–utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β‐thalassemia patients. Transfusion. 2013;53:1722–9.
pubmed: 23241074
Emamgholipour S, Ahmadi B, Rajabi AH, Azarkeivan A, Ebrahimi M, Esmaeilzadeh F. Cost-utility of treatment of the patients with Thalassemia Major in Iran. The Scientific Journal of Iranian Blood Transfusion Organization. 2018;15:257–64.
Rasekh HR, Imani A, Karimi M, Golestani M. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. ClinicoEcon Outcomes Res. 2011;3:207.
pubmed: 22163168
pmcid: 3234155
Pourkhajoei S, Barouni M, Noroozi A, Hajebi A, Amini S, Karamouzian M, Sharifi H. Cost-effectiveness of methadone maintenance treatment centers in prevention of human immunodeficiency virus infection. Addiction Health. 2017;9:81.
pubmed: 29299210
pmcid: 5742414
Ghiasvand H, Moradi-Joo M, Abolhassani N, Ravaghi H, Raygani SM, Mohabbat-Bahar S. Economic evaluation of resistant major depressive disorder treatment in Iranian population: a comparison between repetitive Transcranial Magnetic Stimulation with electroconvulsive. Med J Islamic Republic of Iran. 2016;30:330.
Mazdaki A, Ghiasvand H, Asiabar AS, Naghdi S, Aryankhesal A. Economic evaluation of test-and-treat and empirical treatment strategies in the eradication of Helicobacter pylori infection; A Markov model in an Iranian adult population. Med J Islamic Republic of Iran. 2016;30:327.
pubmed: 27390697
pmcid: 4898868
Ravaghi H, Ebrahimnia M, Rostami-Farzaneha Z, Madani MHH. Cost-effectiveness analysis of screening chronic kidney disease in Iran. J Clin Diagn Res. 2019;13:1.
Nemati H, Talebianpour H, Lotfi F, Sepehri NZ, Keshavarz K. Cost-effectiveness analysis of topiramate versus phenobarbital in the treatment of children with febrile seizure in Shiraz. Iran J Child Neurol. 2019;13:109–20.
pubmed: 31645871
pmcid: 6789090
Moradpour A, Hadian M, Tavakkoli M. Economic evaluation of End Stage Renal Disease treatments in Iran. Clin Epidemiol Global Health. 2019.
Moradi N, Tofighi S, Akbari Sari A. Economic evaluation of infliximab for treatment of refractory ulcerative colitis in Iran: cost-effectiveness analysis. Iran J Pharm Sci. 2016;12:33–42.
Davoodi Lahijan J, Farrokh-Eslamlou H, Shariat Torbaghan K, Nouraei Motlagh S, Yusefzadeh H. COST EFFECTIVENESS ANALYSIS OF VARNISH FLUORIDE THERAPY OF STUDENTS IN URMIA’S PRIMARY SCHOOLS. J Nurs Midwif Urmia Univ Med Sci. 2019;17:204–12.
Behnamfar Z, Shahkarami V, Sohrabi S, Aghdam AS, Afzali H. Cost and effectiveness analysis of the diagnostic and therapeutic approaches of group A Streptococcus pharyngitis management in Iran. J Family Med Primary Care. 2019;8:2942.
Tasavon Gholamhoseini M, Barouni M, Afsharzadeh N, Jafar iSirizi M. Cost-effectiveness of growth hormone (Somatropin) for the treatment of children with short stature. Payavard Salamat. 2018;12:286–95.
GBD Compare. | Viz Hub. https://www.vizhub.healthdata.org/gbd-compare/ .
Smith S, Nolan A, Normand C, McPake B. Health economics: an international perspective. London: Routledge; 2013.
Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ. 2000;9:681–98.
pubmed: 11137950
Tu H-AT, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature. Expert Rev Vaccines. 2011;10:1037–51.
pubmed: 21806398
Baltussen RM, Adam T, Tan-Torres Edejer T, Hutubessy RC, Acharya A, Evans DB, Murray CJ, Organization WH. Making choices in health: WHO guide to cost-effectiveness analysis. 2003.
Hoque ME, Khan JA, Hossain SS, Gazi R, Rashid H-a, Koehlmoos TP, Walker DG. A systematic review of economic evaluations of health and health-related interventions in Bangladesh. Cost Effectiveness Resource Allocation. 2011;9:1.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–38.
pubmed: 8246705
Rascati K. Essentials of pharmacoeconomics. New York: Lippincott Williams & Wilkins; 2013.
Iranian Registry of Clinical Trials [ https://irct.ir/ ].
Javadinasab H, Daroudi R, Salimzadeh H, Delavari A, Vezvaie P, Malekzadeh R. Cost-effectiveness of screening colonoscopy in Iranian High Risk Population. ArchIran Med. 2017;20:1.
Hatam N, Dehghani M, Habibian M, Jafari A. Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractory hodgkin and non-hodgkin’s lymphoma in Iran. Iran J Cancer Prev. 2015;8:1.
Nahvijou A, Daroudi R, Tahmasebi M, Hashemi FA, Hemami MR, Sari AA, Marenani AB, Zendehdel K. Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PLoS ONE. 2016;11:e0156705.
pubmed: 27276093
pmcid: 4898767
Ghaderi H, Shafiee H, Ameri H, VafaeeNasab M. Cost-effectiveness of home care and hospital care for stroke patients. Health Care Management. 2013;4:1.